Facebook
Twitter
LinkedIn
ForwardFundamentals in Urology Webcast (2018)
Specifically designed for anyone unable to get away from the office to attend the Live Course - the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. New topics for this year include Reflux, Obstruction, and Undescended Testes- Causes and Clinical Implications and Medical and Surgical Management of ED. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
Purchase of the Fundamentals in Urology Webcast (2018) will also include additional educational resources in the following topic areas:
- Pathology
- Urodynamics
- Uro-Ethics
- Obstructive Uropathy
- Applications Outcome
- Renal Physiology
Target Audience
- Residents
- APN/PA
Learning Objectives
After completing this activity, the learner will be able to:
- Describe the basic pathophysiology of nephrolithiasis
- Identify the indications and options for the medical evaluation of recurrent and first time stone formers.
- Establish an effective algorithm for the medical management of nephrolithiasis.
- Identify the true incidence of IC/BPS and CP/CPPS in the US population
- Identify what is currently believed about the pathophysiology of chronic pelvic pain
- Describe how to use the AUA guidelines to develop a treatment plan for patients with IC/BPS and CP/CPPS
- Review current research in pelvic pain and possible new treatment options
- Apply knowledge of lower urinary tract function and electronic measurement of pressure, flow and electromyography to performance of a multichannel urodynamic test including prestudy uroflowmetry, filling cystometrogram and voiding pressure flow study
- Review salient concepts of vesicoureteral reflux, urinary tract obstruction and cryptorchidism with urology residents in the early stages of their urology residency training curriculum.
- Explain the basic development of the lower and upper urinary tract including the bladder, kidney and ureters
- Identify clinical situations that may be encountered if aberrant development occurs in any of the above organ systems
- Distinguish when the presence of bacteria or fungi in the urinary tract need to be treated, and when they don’t
- Explain the basic development of the lower and upper urinary tract including the bladder, kidney and ureters.
- Identify the medical therapies designed to address benign enlargement of the prostate.
- Explain the basic physics underlying laser energy, physiologic changes attributable to pneumoperitoneum, and mechanisms to improve outcomes of shock wave lithotripsy.
- Explain male reproductive anatomy and physiology
- Describe a basic clinical overview of male reproductive medicine and surgery
- Describe the history of M1 Prostate cancer therapies.
- Identify basics in ADT management.
- Discuss basic science and clinical outcomes of new therapies.
- Review the anatomy and physiology of the lower urinary tract as it relates to bladder storage and voiding.
- Describe the innervation of the lower urinary tract and the principle mechanisms by which the central and peripheral nervous systems control urine storage and micturition.
- Explain the pathophysiological findings related to bladder dysfunction in specific neurological conditions.
- Discuss the pathophysiology, evaluation strategy, and treatment options for overactive bladder.
- Discuss the rationale behind selection of segment of bowel used in urinary diversion
- Explain the long term consequences of metabolic changes after urinary diversion and how to mitigate them
- Describe the surgical principle of compliance and how it relates to surgical technique
- Define the fundamentals of adrenal anatomy and physiology integrate into the care of the urologic patient.
- Describe the genetic basis and current clinical and surgical management of all types of localized as well as advanced kidney cancer.
Session 1: Stones, Urodynamics and Inflammation
- Nephrolithiasis: Physiology, Metabolic Work‐up and Treatment of Stone, Glenn Preminger, MD
- Urodynamics, Mikel Gray, PhD
- Interstitial Cystitis and Disorders of Pelvic Pain, Robert J. Evans, MD, FACS
Session 2: Pediatrics
- Embryology, Congenital Anomalies, and Disorders of Sexual Differentiation, Patricio C. Gargollo, MD
- Reflux, Obstruction, and Undescended Testes – Causes and Clinical Implications, Shukla Aseem, MD
Session 3: Urologic Imaging and Infections
- MRI for Urologist, Nabeel Sarwani, MD
- Urologic Infections: Etiology, Patterns and Pathophysiology, Michel A. Pontari, MD
Session 4: BPH and Science of Minimally Invasive Surgery
- BPH: Pathophysiology, Drugs, and Trial, Richard K. Lee, MD
- Lasers, Laparoscopes, and Lithotripters: The Science of Minimally Invasive Urology, Jay D. Raman, MD, FACS
Session 5: Infertility and Erectile Dysfunction
- Infertility and Reproductive Biology in Women and Men, Cigdem Tanrikut, MD
- Medical and Surgical Management of ED, John Mulhall, MD
- AUA Update, Victor Nitti, MD
Session 6: Prostate Cancer
- PSA, Urine Markers and the Science of Cancer Screening, Leonard G. Gomella, MD, FACS
- Management of Advanced Prostate Cancer: Drugs, Mechanisms, Disease, Epidemiology and Molecular Mechanisms, Michael B. Williams, MD
Session 7: Bladder Neurobiology and Pelvic Organ Prolapse
- Lower Urinary Tract Neurobiology and Functional Bladder Disorders, Gary Lemack, MD
- Pelvic Organ Prolapse and SUI: Mechanisms and Mechanics, Victor Nitti, MD
Session 8: Bladder Cancer and Bowel Diversions
- Basic Science of Bladder Cancer, Trinity J. Bivalacqua, MD
- Bowel Diversions: Physiology Underlying Electrolyte Abnormalities, Tracey Krupski, MD, MPH
Session 9: Adrenal Disorders and Kidney Cancer
- Adrenal Physiology, Alexander Kutikov, MD, FACS
- Molecular Genetics and Principles of Molecular Therapeutics of Kidney Cancer, W. Marston Linehan, MD
Optional Pathology and Urdoyndamics Modules (from 2017 course)
- Pathology, Gladell Paner, MD
- Urodynamics, Mikel Gray, PhD
Additional Educational Modules (from 2017 course)
- Uro-Ethics, Eric A. Singer, MD
- Obstructive Uropathy: Valves and UPJO, C.D. Anthony Herndon, MD, FAAP, FACS
- Application of Outcomes Research to Urologic Patients, Charles D. Scales Jr., MD
- Renal Physiology Changes in Pathologic States, Necole Marie Streeper, MD
| Faculty Disclosures: | |||
| Name | Company | Role | Financial |
| Trinity J. Bivalacqua, MD | photocure | Meeting Participant or Lecturer,Scientific Study or Trial | No |
| taris | Scientific Study or Trial | No | |
| taris | Scientific Study or Trial | No | |
| FKD | Scientific Study or Trial | No | |
| Genetech | Scientific Study or Trial | No | |
| Robert J. Evans, MD | allergan | Scientific Study or Trial | Yes |
| urigen | Investment Interest | Yes | |
| allergan | Scientific Study or Trial | Yes | |
| TARIS | Scientific Study or Trial | Yes | |
| aquinox | Consultant or Advisor,Scientific Study or Trial | Yes | |
| Patricio C. Gargollo, MD | Intuitive Surgical | Meeting Participant or Lecturer | Yes |
| Leonard G. Gomella, MD | Astellas | Consultant or Advisor | Yes |
| Janssen | Consultant or Advisor | Yes | |
| Wolters Kluwer | Health Publishing | Yes | |
| McGraw Hill | Health Publishing | Yes | |
| Merck Manual | Health Publishing | Yes | |
| Canadian Journal of Urology | Health Publishing | Yes | |
| MDx Health | Consultant or Advisor | Yes | |
| Merck Pharmaceuticals | Consultant or Advisor | Yes | |
| Bayer | Consultant or Advisor | Yes | |
| Mikel L. Gray, Ph.D. | Laborie Medical | Scientific Study or Trial | Yes |
| 3M Inc | Consultant or Advisor | Yes | |
| Tracey Krupski, MD | Argos | Scientific Study or Trial | No |
| FKD - Instilidrin | Scientific Study or Trial | No | |
| American Cancer Society | Scientific Study or Trial | Yes | |
| NIH | Scientific Study or Trial | No | |
| Alexander Kutikov, MD | UrologyMatch.com LLC | Leadership Position | Yes |
| Visible Health, Inc | Leadership Position | Yes | |
| Richard K. Lee, MD | |||
| Gary E. Lemack, MD | Allergan | Consultant or Advisor,Meeting Participant or Lecturer | Yes |
| Roivant | Consultant or Advisor | Yes | |
| Avadel | Consultant or Advisor | Yes | |
| W. Marston Linehan, MD | |||
| John P. Mulhall, MD | Association of Peyronie's Disease Advocates (APDA) | Leadership Position | No |
| Victor W. Nitti, MD | Astellas | Health Publishing,Scientific Study or Trial | No |
| Allergan | Health Publishing,Scientific Study or Trial | No | |
| Serenity Pharmeuticals | Investment Interest | Yes | |
| Medtronic | Scientific Study or Trial | No | |
| Michel A. Pontari, MD | Lilly | Consultant or Advisor | Yes |
| aquinox | Consultant or Advisor,Scientific Study or Trial | Yes | |
| Glenn M. Preminger, MD | Boston Scientific | Consultant or Advisor | Yes |
| UpToDate | Health Publishing | Yes | |
| Retrophin | Consultant or Advisor,Meeting Participant or Lecturer | Yes | |
| Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
| MDx Health | Scientific Study or Trial | No | |
| Nabeel Sarwani, MD | |||
| Aseem R. Shukla, MD | |||
| Cigdem Tanrikut, MD | New England Cryogenic Center | Other | Yes |
| Fertility Research and Practice | Health Publishing | No | |
| Michael B. Williams, M.D. | Astellas | Scientific Study or Trial | No |
| Jannsen | Scientific Study or Trial | No | |
| Pacific Edge Diagnostics | Consultant or Advisor | Yes | |
| Online Educational Modules and Optional Course Faculty: | |||
| Name | Company | Role | Financial |
| Mikel L. Gray, Ph.D. | Laborie Medical | Meeting Participant or Lecturer | Yes |
| 3M Inc. | Consultant or Advisor | Yes | |
| C.D. Anthony Herndon, MD, FAAP, FACS | Nothing to disclose. | ||
| Gladell Paner, MD | Amirsys, Inc. | Health Publishing | Yes |
| Charles D. Scales Jr., MD | NIH/National Institute on Aging | Scientific Study or Trial | Yes |
| Society of Urology Chairpersons and Program Directors | Scientific Study or Trial | Yes | |
| Filament Biosolutions | Scientific Study or Trial | No | |
| NIH/ National Institute of Diabetics and Digestive and Kidney Diseases | Scientific Study or Trial | No | |
| Gilead | Consultant or Advisor | Yes | |
| Astra-Zeneca | Scientific Study or Trial | Yes | |
| Eric A. Singer, MD | Nothing to disclose. | ||
| Necole M Streeper, M.D. | Nothing to disclose. | ||
| Education Council Disclosures: | |||
| Name | Company | Role | Financial |
| Michael R. Abern, MD | Department of Defense Prostate Cancer Research Program | Scientific Study or Trial | Yes |
| American Urological Association Office of Education | Consultant or Advisor | Yes | |
| Department of Defense Prostate Cancer Research Program | Consultant or Advisor | Yes | |
| Sero Andonian, MD | Lumenis | Meeting Participant or Lecturer, Scientific Study or Trial | Yes |
| Timothy Charles Brand, MD | Nothing to disclose | ||
| Anthony A. Caldamone, MD | Nothing to disclose | ||
| Matthew S. Christman, MD | Nothing to disclose | ||
| John D. Denstedt, MD | Cook Urology | Owner, Product Development | Yes |
| Endourological Society | Leadership Position | Yes | |
| Endourological Society | Health Publishing | Yes | |
| Jody Donaldson | Nothing to disclose | ||
| Shelby Englert | Nothing to disclose | ||
| Allen Gao, MD, PhD | Pandomedx | Leadership Position, Owner, Product Development | Yes |
| Matthew Thomas Gettman, MD | COVR Medical | Consultant or Advisor | Yes |
| Intuitive Surgical | Consultant or Advisor | Yes | |
| Exact Sciences | Scientific Study or Trial | Yes | |
| Howard B. Goldman, MD | allergan | Consultant or Advisor | Yes |
| Medtronic | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Cook | Scientific Study or Trial | No | |
| Nuvectra | Consultant or Advisor | Yes | |
| Axonics | Consultant or Advisor | Yes | |
| NewUro | Consultant or Advisor | Yes | |
| Galvani | Consultant or Advisor | Yes | |
| bioness | Scientific Study or Trial | No | |
| William C. Huang, MD | Photocure | Scientific Study or Trial | Yes |
| Karl Storz | Scientific Study or Trial | Yes | |
| Intuitive | Meeting Participant or Lecturer | Yes | |
| William C. Hulbert, Jr., MD | Nothing to disclose | ||
| Brant Inman, MD, MS, FRCSC | Dendreon | Scientific Study or Trial | No |
| Genentech Inc | Scientific Study or Trial | No | |
| Combat Medical | Consultant or Advisor, Scientific Study or Trial | Yes | |
| FKD Therapies | Scientific Study or Trial | No | |
| Nucleix | Scientific Study or Trial | Yes | |
| Urogen | Scientific Study or Trial | Yes | |
| Mark L. Jordan MD,FACS | Nothing to disclose | ||
| Martin A. Koyle, MD | Nothing to disclose | ||
| Yair Lotan, MD | abbott | Scientific Study or Trial | No |
| Cepheid | Consultant or Advisor, Scientific Study or Trial | No | |
| Pacific Edge | Scientific Study or Trial | No | |
| FKD | Scientific Study or Trial | No | |
| MDxHealth | Consultant or Advisor, Scientific Study or Trial | Yes | |
| biocancell | Scientific Study or Trial | No | |
| GenomeDx Biosciences Inc | Scientific Study or Trial | No | |
| photocure | Consultant or Advisor, Scientific Study or Trial | No | |
| Nicole Lara Miller, MD | Boston Scientific Corporation | Consultant or Advisor, Meeting Participant or Lecturer | Yes |
| Practical Reviews In Urology | Health Publishing | Yes | |
| Manoj Monga, MD, FACS | Fortec | Other | Yes |
| Ajay Kumar Nangia, MBBS, FACS | AUA News | Leadership Position, Health Publishing | Yes |
| NIH CCN Trial | Scientific Study or Trial | Yes | |
| Urology Care Foundation | Leadership Position | No | |
| AUA Health Policy Council | Leadership Position | No | |
| South Central AUA | Leadership Position | No | |
| ASRM | Leadership Position | No | |
| Curtis Nickel, MD | Farr Laboratories | Consultant or Advisor | Yes |
| Aquinox | Scientific Study or Trial | No | |
| PureTech Health | Consultant or Advisor | Yes | |
| AUA | Health Publishing | Yes | |
| NIH | Scientific Study or Trial | Yes | |
| Canadian Institute of Health Research | Scientific Study or Trial | Yes | |
| Interface Biologics | Consultant or Advisor | Yes | |
| Alvio Therapeutics | Consultant or Advisor | Yes | |
| Seikagaku Corporation | Consultant or Advisor | Yes | |
| Medifocus | Consultant or Advisor | Yes | |
| RedLeaf Medical | Consultant or Advisor | Yes | |
| Victor William Nitti, MD | Astellas | Health Publishing, Scientific Study or Trial | No |
| Allergan | Health Publishing, Scientific Study or Trial | No | |
| Serenity Pharmeuticals | Investment Interest | Yes | |
| Medtronic | Scientific Study or Trial | No | |
| Christopher Porter, MD | Nothing to disclose | ||
| Ganesh V. Raj, MD, PhD | Ptares | Owner, Product Development | Yes |
| C-diagnostics corp | Consultant or Advisor, Investment Interest | Yes | |
| amgen | Meeting Participant or Lecturer | Yes | |
| Johnson and Johnson | Consultant or Advisor, Owner, Product Development | Yes | |
| Astellas | Meeting Participant or Lecturer | Yes | |
| ASTELLAS | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Janssen | Owner, Product Development | Yes | |
| BAYER | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| SANOFI | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| GaudiumRx | Leadership Position, Investment Interest, Owner, Product Development | Yes | |
| Medivation | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| EtiraRx | Leadership Position, Investment Interest, Owner, Product Development | Yes | |
| Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
| MDx Health | Scientific Study or Trial | No | |
| Lee Richstone, MD | Nothing to disclose | ||
| Heather Schultz | SUNA | Meeting Participant or Lecturer | Yes |
| SUNA | Leadership Position | No | |
| Karl-Dietrich Sievert, MD, PhD | Medtronics | Meeting Participant or Lecturer, Scientific Study or Trial | Yes |
| Allergen | Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Neotract | Meeting Participant or Lecturer | Yes | |
| Stimguard | Meeting Participant or Lecturer, Scientific Study or Trial | Yes | |
| Joseph A. Smith Jr., MD | Nothing to disclose | ||
| Ryan Patrick Terlecki, MD, FACS | American Medical Systems | Consultant or Advisor, Other | Yes |
| Boston Scientific | Consultant or Advisor | Yes | |
| MicroGen Dx | Consultant or Advisor | Yes | |
| U.S. Department of Defense | Scientific Study or Trial | Yes | |
| Edouard John Trabulsi, MD, FACS | GenomeDx | Consultant or Advisor | Yes |
| Janssen | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Pfizer | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
| Merck | Meeting Participant or Lecturer | Yes | |
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 33.50 hours
Release Date: June, 2018
Expiration Date: June, 2021
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring activity for a maximum of 33.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.